Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 62

1.

Influence of phosphatidylserine and phosphatidylethanolamine on farnesol tolerance in Candida albicans.

Hasim S, Vaughn EN, Donohoe D, Gordon DM, Pfiffner S, Reynolds TB.

Yeast. 2017 Nov 16. doi: 10.1002/yea.3297. [Epub ahead of print]

PMID:
29143357
2.

Manipulating Glucose Metabolism during Different Stages of Viral Pathogenesis Can Have either Detrimental or Beneficial Effects.

Varanasi SK, Donohoe D, Jaggi U, Rouse BT.

J Immunol. 2017 Sep 1;199(5):1748-1761. doi: 10.4049/jimmunol.1700472. Epub 2017 Aug 2.

PMID:
28768727
3.

Evaluation of the MiStent sustained sirolimus eluting biodegradable polymer coated stent for the treatment of coronary artery disease: does uniform sustained abluminal drug release result in earlier strut coverage and better safety profile?

Tijssen RYG, Kraak RP, Lu H, Mifek JG, Carlyle WC, Donohoe DJ, De Winter RJ, Koch KT, Wykrzykowska JJ.

Expert Rev Med Devices. 2017 May;14(5):325-334. doi: 10.1080/17434440.2017.1318057. Epub 2017 Apr 24.

PMID:
28402204
4.

Characterization of the Pro-Inflammatory Cytokine IL-1β on Butyrate Oxidation in Colorectal Cancer Cells.

Johnstone M, Bennett N, Standifer C, Smith A, Han A, Bettaieb A, Whelan J, Donohoe DR.

J Cell Biochem. 2017 Jun;118(6):1614-1621. doi: 10.1002/jcb.25824. Epub 2017 Jan 11.

PMID:
27922186
5.

Technical overview on the MiStent coronary stent.

McCLAIN JB, Carlyle WC, Donohoe DJ, Ormiston JA.

Minerva Cardioangiol. 2016 Oct;64(5):560-71. Epub 2016 May 6. Review.

PMID:
27152624
6.

Cellular Metabolism and Dose Reveal Carnitine-Dependent and -Independent Mechanisms of Butyrate Oxidation in Colorectal Cancer Cells.

Han A, Bennett N, MacDonald A, Johnstone M, Whelan J, Donohoe DR.

J Cell Physiol. 2016 Aug;231(8):1804-13. doi: 10.1002/jcp.25287. Epub 2015 Dec 28.

PMID:
26661480
7.

Evaluation of a crystalline sirolimus-eluting coronary stent with a bioabsorbable polymer designed for rapid dissolution: two-year outcomes from the DESSOLVE I and II trials.

Wijns W, Suttorp MJ, Zagozdzon L, Morice MC, McClean D, Stella P, Donohoe D, Knape C, Ormiston J.

EuroIntervention. 2016 Jun 20;12(3):352-5. doi: 10.4244/EIJY15M09_14.

8.

Light Chain Amyloid Fibrils Cause Metabolic Dysfunction in Human Cardiomyocytes.

McWilliams-Koeppen HP, Foster JS, Hackenbrack N, Ramirez-Alvarado M, Donohoe D, Williams A, Macy S, Wooliver C, Wortham D, Morrell-Falvey J, Foster CM, Kennel SJ, Wall JS.

PLoS One. 2015 Sep 22;10(9):e0137716. doi: 10.1371/journal.pone.0137716. eCollection 2015.

9.

IL-1β reciprocally regulates chemokine and insulin secretion in pancreatic β-cells via NF-κB.

Burke SJ, Stadler K, Lu D, Gleason E, Han A, Donohoe DR, Rogers RC, Hermann GE, Karlstad MD, Collier JJ.

Am J Physiol Endocrinol Metab. 2015 Oct 15;309(8):E715-26. doi: 10.1152/ajpendo.00153.2015. Epub 2015 Aug 25.

10.

Interleukin-23 Increases Intestinal Epithelial Cell Permeability In Vitro.

Heinzerling NP, Donohoe D, Fredrich K, Gourlay DM, Liedel JL.

Eur J Pediatr Surg. 2016 Jun;26(3):260-6. doi: 10.1055/s-0035-1551563. Epub 2015 May 22.

PMID:
26007691
11.

Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial.

Garcia L, Jaff MR, Metzger C, Sedillo G, Pershad A, Zidar F, Patlola R, Wilkins RG, Espinoza A, Iskander A, Khammar GS, Khatib Y, Beasley R, Makam S, Kovach R, Kamat S, Leon LR Jr, Eaves WB, Popma JJ, Mauri L, Donohoe D, Base CC, Rosenfield K; SUPERB Trial Investigators.

Circ Cardiovasc Interv. 2015 May;8(5). pii: e000937. doi: 10.1161/CIRCINTERVENTIONS.113.000937. Erratum in: Circ Cardiovasc Interv. 2015 Jun;8(6). pii: e000014. doi: 10.1161/HCV.0000000000000014.

12.

Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.

Wettersten HI, Hakimi AA, Morin D, Bianchi C, Johnstone ME, Donohoe DR, Trott JF, Aboud OA, Stirdivant S, Neri B, Wolfert R, Stewart B, Perego R, Hsieh JJ, Weiss RH.

Cancer Res. 2015 Jun 15;75(12):2541-52. doi: 10.1158/0008-5472.CAN-14-1703. Epub 2015 May 7.

13.

PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.

Abu Aboud O, Donohoe D, Bultman S, Fitch M, Riiff T, Hellerstein M, Weiss RH.

Am J Physiol Cell Physiol. 2015 Jun 1;308(11):C890-8. doi: 10.1152/ajpcell.00322.2014. Epub 2015 Mar 25.

14.

A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner.

Donohoe DR, Holley D, Collins LB, Montgomery SA, Whitmore AC, Hillhouse A, Curry KP, Renner SW, Greenwalt A, Ryan EP, Godfrey V, Heise MT, Threadgill DS, Han A, Swenberg JA, Threadgill DW, Bultman SJ.

Cancer Discov. 2014 Dec;4(12):1387-97. doi: 10.1158/2159-8290.CD-14-0501. Epub 2014 Sep 29.

15.

Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study.

Rusinaru D, Vrolix M, Verheye S, Chowdhary S, Schoors D, Di Mario C, Desmet W, Donohoe DJ, Ormiston JA, Knape C, Bezerra H, Lansky A, Wijns W; DESSOLVE II Investigators.

Catheter Cardiovasc Interv. 2015 Dec 1;86(7):1141-50. doi: 10.1002/ccd.25610. Epub 2015 Sep 22.

PMID:
25044635
16.

Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial.

Wijns W, Vrolix M, Verheye S, Schoors D, Slagboom T, Gosselink M, Benit E, Donohoe D, Knape C, Attizzani GF, Lansky AJ, Ormiston J; DESSOLVE II Investigators.

EuroIntervention. 2015 Apr;10(12):1383-90. doi: 10.4244/EIJY14M05_03.

17.

First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).

Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W.

JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013. Epub 2013 Sep 18.

18.

Serial assessment by optical coherence tomography of early and late vascular responses after implantation of an absorbable-coating Sirolimus-Eluting stent (from the first-in-human DESSOLVE I trial).

Attizzani GF, Bezerra HG, Ormiston J, Wang W, Donohoe D, Wijns W, Costa MA.

Am J Cardiol. 2013 Nov 15;112(10):1557-64. doi: 10.1016/j.amjcard.2013.07.013. Epub 2013 Aug 29.

PMID:
23992957
19.

The BRG1 chromatin remodeler regulates widespread changes in gene expression and cell proliferation during B cell activation.

Holley DW, Groh BS, Wozniak G, Donohoe DR, Sun W, Godfrey V, Bultman SJ.

J Cell Physiol. 2014 Jan;229(1):44-52. doi: 10.1002/jcp.24414.

PMID:
23757284
20.

Microbial oncotarget: bacterial-produced butyrate, chemoprevention and Warburg effect.

Donohoe DR, Curry KP, Bultman SJ.

Oncotarget. 2013 Feb;4(2):182-3. No abstract available.

Supplemental Content

Loading ...
Support Center